Arbutus Biopharma (ABUS) Revenue (2013 - 2026)

Arbutus Biopharma has disclosed Revenue across 14 years of filings, most recently posting $179.1 million for Q1 2026.

• Revenue for Q1 2026 came in at $179.1 million, up 10054.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $191.4 million (up 2889.93% YoY), and the FY2025 annual result was $14.1 million, up 128.21% from the prior year.
• Revenue came in at $179.1 million for Q1 2026 at Arbutus Biopharma, up from $1.1 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $179.1 million in Q1 2026 to a low of $529000.0 in Q3 2025.
• The 5-year median for Revenue is $4.7 million (2023), against an average of $15.1 million.
• Across the five-year window, Revenue slumped 77.09% in 2024 and surged 10054.54% in 2026, its largest moves.
• Arbutus Biopharma's Revenue stood at $6.2 million in 2022, then slumped by 65.65% to $2.1 million in 2023, then declined by 26.62% to $1.6 million in 2024, then sank by 33.23% to $1.1 million in 2025, then surged by 16943.39% to $179.1 million in 2026.
• The last three Revenue figures came in at $179.1 million (Q1 2026), $1.1 million (Q4 2025), and $529000.0 (Q3 2025), per Business Quant data.